Prof Stephen Nicholls

Director, Victorian Heart Hospital and Victorian Heart Institute, Clayton, Australia

Assoc Prof David Sullivan

Physician and Chemical Pathologist, Department of Clinical Biochemistry, Royal Prince Alfred Hospital, New South Wales, Australia

Assoc Prof Karam Kostner

Director of Cardiology, Mater Public and Private Hospital, Brisbane, Australia

Home > Cardiology CME/CE Webinar > Webinar > Lipoprotein(a): The science behind the Risk Factor

Lipoprotein(a): The science behind the Risk Factor

6 May 2024

KEY TAKEAWAYS

Higher Lipoprotein(a) levels are associated with increased rate of CVD. The recent 2019 ESC guidelines recommend Lp(a) biomarker testing at least once in each adult person’s life.
Challenges to implementation of Lp(a) biomarker testing include access, feasibility, affordability and impact on outcomes.
Patients with elevated Lipoprotein(a) levels with elevated risk of CVD should be treated to reduce LDL levels.

Updates from Leading Experts

proCardio Asia Pacific

STRONG-HF: Implementation of GDMT Heart Failure Therapy & Post-discharge Heart Failure Management

Prof Alexandre Mebazaa shares the key results and highlights from the STRONG-HF study of implementation of GDMT heart failure therapy that assessed the safety, tolerability of optimization of guideline directed...

28 March 2023

Prof Alexandre Mebazaa

proCardio Asia Pacific

DROP Asian ACS – Study Results and Practical Approach

10 November 2025

Dr Kenji Inoue